Distinguished in Mycetoma

Dr. Michael J. Hall

Family Medicine
6008 W Bell Rd Ste 101, 
Glendale, AZ 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in Mycetoma
6008 W Bell Rd Ste 101, 
Glendale, AZ 
OverviewInsuranceLocationsClinical Research

Overview

Michael Hall is a primary care provider, practicing in Family Medicine in Glendale, Arizona. Dr. Hall is rated as a Distinguished provider by MediFind in the treatment of Mycetoma. His top areas of expertise are Colorectal Cancer, Mycetoma, Familial Colorectal Cancer, Stent Placement, and Colonoscopy.

His clinical research consists of co-authoring 174 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Family Medicine
Licenses
Family Medicine in OR
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

6008 W Bell Rd Ste 101, Glendale, AZ 85308

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Drug, Procedure
Study Drug: Olaparib
Study Phase: Phase 2
A Phase Ib/II Clinical Trial of Nous-209 for Recurrent Neoantigen Immunogenicity and Cancer Immune Interception in Lynch Syndrome
A Phase Ib/II Clinical Trial of Nous-209 for Recurrent Neoantigen Immunogenicity and Cancer Immune Interception in Lynch Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: October 17, 2025
Intervention Type: Procedure, Biological, Other
Study Drugs: Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP, MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP
Study Phase: Phase 1/Phase 2
Impact of Atorvastatin ± Aspirin on Colorectal Biomarkers in Patients With Lynch Syndrome: a Pilot Study
Impact of Atorvastatin ± Aspirin on Colorectal Biomarkers in Patients With Lynch Syndrome: a Pilot Study
Enrollment Status: Completed
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drugs: Atorvastatin, Aspirin
Study Phase: Early Phase 1
View 2 Less Clinical Trial

174 Total Publications

Weak hydrogen bonding in the structures of three double-acylated aminoantipyrines.
Weak hydrogen bonding in the structures of three double-acylated aminoantipyrines.
Journal: Acta crystallographica. Section C, Structural chemistry
Published: November 10, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hall's expertise for a condition
ConditionClose
    View All 16 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile